{"id":3354,"date":"2021-11-17T10:04:58","date_gmt":"2021-11-17T10:04:58","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=3354"},"modified":"2022-01-13T10:36:49","modified_gmt":"2022-01-13T10:36:49","slug":"ana-maria-orbai-acr-2021-effect-of-guselkumab-on-general-health-outcomes-using-the-promis-29","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/psoriatic-arthritis\/conference-hub\/ana-maria-orbai-acr-2021-effect-of-guselkumab-on-general-health-outcomes-using-the-promis-29\/","title":{"rendered":"Ana-Maria Orbai, ACR 2021: Effect of Guselkumab on General Health Outcomes using the PROMIS-29"},"content":{"rendered":"

touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orba<\/strong>i (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796).<\/span><\/p>\n

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.<\/b><\/p>\n

The abstract entitled<\/span> \u2018<\/span>Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial<\/strong><\/em><\/span><\/a>\u2019 (Abstract number: 1332) was presented at the ACR Convergence, 5-9 November.<\/span><\/p>\n

Questions<\/strong><\/p>\n

    \n
  1. Could you give us an overview of the symptoms that negatively impact health-related quality of life in psoriatic arthritis (PsA)? (0:19)<\/span><\/li>\n
  2. Why was it important to validate the PROMIS-29 profile in patients with active psoriatic arthritis? (0:52)<\/span><\/li>\n
  3. What did the DISCOVER-1 analysis teach us about the impact of guselkumab on joint and skin clinical manifestations of PsA? (1:55)<\/span><\/li>\n
  4. Could you tell us a little about the objectives and findings from this current analysis? (2:50)<\/span><\/li>\n
  5. What will be the likely role of guselkumab in the treatment paradigm for PsA? (4:22)<\/span><\/li>\n<\/ol>\n

    Disclosures:<\/strong> Dr Ana-Orbai has acted as a consultant for Eli Lilly, Novartis, Janssen, Pfizer and UCB, and received grant\/ research support from AbbVie, Eli Lilly, Celgene, Janssen and Horizon. <\/span><\/p>\n

    Support:<\/strong>\u00a0Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.<\/p>\n

    Filmed in coverage of virtual ACR Convergence 2021.<\/strong><\/em><\/p>\n

     <\/p>\n

     <\/p>\n

     <\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796). This information is brought to […]<\/p>\n","protected":false},"featured_media":3355,"template":"","class_list":["post-3354","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-psoriatic-arthritis","video_categories-acr-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/3354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":3,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/3354\/revisions"}],"predecessor-version":[{"id":3801,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/3354\/revisions\/3801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/3355"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=3354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}